Biotech Volatile Stocks: NewLink Genetics Corp (NASDAQ:NLNK), Alnylam Pharmaceuticals (NASDAQ:ALNY), Kindred Biosciences (NASDAQ:KIN), Agenus (NASDAQ:AGEN)



NewLink Genetics Corp (NASDAQ:NLNK)’s algenpantucel-L is expected to garner the highest sales and will be launched in both resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398,” director says. NewLink Genetics Corp (NASDAQ:NLNK) stock performance was -9.03% in last session and finished the day at $24.98. Traded volume was 808,573.00million shares in the last session and the average volume of the stock remained 627.75K shares. NewLink Genetics Corp (NASDAQ:NLNK) insider ownership is 3.70%.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) dropped -5.97 percent to $61.70 Thursday on volume of 954,917.00million shares. The intra-day range of the stock was $60.75 to $66.19. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a market capitalization of $3.94billion.

Kindred Biosciences, Inc. (NASDAQ:KIN) announced the pricing of its public offering of 3,000,000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by Kindred Bio, upsized from the previously announced public offering of $50,000,000. Kindred Biosciences Inc (NASDAQ:KIN)’s stock on Apr 03, 2014 reported a decrease of -8.97% to the closing price of $18.17. Its fifty two weeks range is $8.75 -$26.99. The total market capitalization recorded $294.85million. The overall volume in the last trading session was 1.03million shares. In its share capital, KIN has 16.23million outstanding shares.

Agenus Inc. (NASDAQ:AGEN) today announced that GlaxoSmithKlines (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients, which contains AgenusQS-21 Stimulon® adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. On Thursday, shares of Agenus Inc (NASDAQ:AGEN) dropped -4.67% to close the day at $3.06. Company return on investment (ROI) is -581.40% and its monthly performance is recorded as -38.43%. Agenus Inc (NASDAQ:AGEN) quarterly revenue growth is 10.07%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone